Biology Reference
In-Depth Information
71Di Raimondo F, Longo G, Cacciola E Jr Milone G, Palumbo GA, Cacciola RR, Alessi M,
Giustolisi R (1996) A good response rate to recombinant erythropoietin alone may be expected in
selected myelodysplastic patients. A preliminary clinical study.
Eur J Haematol
56: 7-11
72 Henry D, Glaspy J (1997) Predicting response to epoetin alfa in anemic cancer patients receiving
chemorx.
Proc Am Soc Clin Oncol
16:49a
73Beguin Y (1998) Prediction of response to optimize outcome of treatment with erythropoietin.
Semin Oncol
25: 27-34
74 Ludwig H, Fritz E (1998) Anemia of cancer patients: Patient selection and patient stratification for
epoetin treatment.
Semin Oncol
25: 35-38
75 Glaspy JA, Jadeja JS, Justice G, Kessler J, Richards D, Schwartzberg L, Tchekmedyian NS,
Armstrong S, O'Byrne J, Rossi G et al. (2002) Darbepoetin alfa given every 1 or 2 weeks allevi-
ates anaemia associated with cancer chemotherapy.
Br J Cancer
87: 268-276
76 Glaspy JA, Jadeja JS, Justice G, Fleishman A, Rossi G, Colowick AB (2003) A randomized,
active-control,pilot trial of front-loaded dosing regimens of darbepoetin alfa for the treatment of
patients with anemia during chemotherapy for malignant disease.
Cancer
97: 1312-1320
77 Glaspy J, Cavill I (1999) Role of iron in optimizing responses of anemic cancer patients to ery-
thropoietin.
Oncology (Huntingt)
13: 461-473
78 Fishbane S, Frei GL, Maesaka J (1995) Reduction in recombinant human erythropoietin doses by
the use of chronic intravenous iron supplementation.
Am J Kidney Dis
26: 41-46
79 Driver PS (1998) Cost-effectiveness impact of iron dextran on hemodialysis patients' use of epo-
etin alfa and blood.
Am J Health Syst Pharm
55: s12-S16
80 Macdougall IC, Chandler G, Elston O, Harchowal J (1999) Beneficial effects of adopting an
aggressive intravenous iron policy in a hemodialysis unit.
Am J Kidney Dis
34: S40-S46
81 Besarab A, Amin N, Ahsan M, Vogel SE, Zazuwa G, Frinak S, Zazra JJ, Anandan JV, Gupta A
(2000) Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients.
J
Am Soc Nephrol
11: 530-538
82 Barosi G, Marchetti M, Liberato NL (1998) Cost-effectiveness of recombinant human erythro-
poietin in the prevention of chemotherapy-induced anaemia.
Br J Cancer
78:781-787
83 Cremieux PY, Finkelstein SN, Berndt ER, Crawford J, Slavin MB (1999) Cost effectiveness, qual-
ity-adjusted life-years and supportive care. Recombinant human erythropoietin as a treatment of
cancer-associated anaemia.
Pharmacoeconomics
16: 459-472
84 Kallich JD, Tchekmedyian NS, Damiano AM, Shi J, Black JT, Erder MH (2002) Psychological
outcomes associated with anemia-related fatigue in cancer patients.
Oncology (Huntingt)
16:
117-124
85 Barnett A (2002) Anemia-related costs for cancer patients.
J Managed Care Med
6: 20-27
86 Berndt ER, Crown B, Finkelstein S, Kallich J, Erder H, Lyman G (2002) Labor force activity in
cancer patients with anemia.
Proc Am Soc Clin Oncol
21: 192b
87Finkelsein S, Berndt E, Crown W, Kallich J, Erder H, Lyman G (2002) Anemia as a pedictor of
high cost in recently diagnosed cancer patients.
Proc Am Soc Clin Oncol
21: 199b
88 Caro JJ, Salas M, Ward A, Goss G (2001) Anemia as an independent prognostic factor for survival
in patients with cancer: A systemic, quantitative review.
Cancer
91: 2214-2221
89Glaspy JA (2002) The potential for anemia treatment to improve survival in cancer patients.
Oncology (Huntingt)
16: 35-40
90 Kallinowski F, Friis RR, Van Roy F, Vaupel P (1990) Oxygenation of tumors derived from ras
transformed cells.
Adv Exp Med Biol
277: 907-916
91 Kallinowski F, Zander R, Hoeckel M, Vaupel P (1990) Tumor tissue oxygenation as evaluated by
computerized-pO
2
- histography.
Int J Radiat Oncol Biol Phys
19: 953-961
92 Vaupel P, Kallinowski F, Okunieff P (1990) Blood flow, oxygen consumption and tissue oxy-
genation of human tumors.
Adv Exp Med Biol
277: 895-905
93Brizel DM, Sibley GS, Prosnitz LR, Scher RL, Dewhirst MW (1997) Tumor hypoxia adversely
affects the prognosis of carcinoma of the head and neck.
Int J Radiat Oncol Biol Phys
38:
285-289
94 Becker A, Hansgen G, Bloching M, Weigel C, Lautenschlager C, Dunst J (1998) Oxygenation of
squamous cell carcinoma of the head and neck: Comparison of primary tumors, neck node metas-
tases, and normal tissue.
Int J Radiat Oncol Biol Phys
42: 35-41
95 Brizel DM, Dodge RK, Clough RW, Dewhirst MW (1999) Oxygenation of head and neck cancer:
Changes during radiotherapy and impact on treatment outcome.
Radiother Oncol
53: 113-117
96 Grogan M, Thomas GM, Melamed I, Wong FL, Pearcey RG, Joseph PK, Portelance L, Crook J,
